Multifunctional IgG/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria vaccine

• Verfasst von: Rosenkranz, Micha [VerfasserIn]
• Verfasst von: Fürle, Kristin [VerfasserIn]
• Verfasst von: Hibbert, Julia [VerfasserIn]
• Verfasst von: Ulmer, Anne [VerfasserIn]
• Verfasst von: Ali, Arin [VerfasserIn]
• Verfasst von: Giese, Thomas [VerfasserIn]
• Verfasst von: Blank, Antje [VerfasserIn]
• Verfasst von: Haefeli, Walter E. [VerfasserIn]
• Verfasst von: Böhnlein, Ernst [VerfasserIn]
• Verfasst von: Lanzer, Michael [VerfasserIn]
• Verfasst von: Thomson-Luque, Richard [VerfasserIn]
• Titel: Multifunctional IgG/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria vaccine
• Verf.angabe: Micha Rosenkranz, Kristin Fürle, Julia Hibbert, Anne Ulmer, Arin Ali, Thomas Giese, Antje Blank, Walter E. Haefeli, Ernst Böhnlein, Michael Lanzer and Richard Thomson-Luque
• Jahr: 2023
• Umfang: 17 S.
• Illustrationen: Illustrationen
• Fussnoten: Veröffentlicht: 09. August 2023 ; Gesehen am 27.09.2023
• Titel Quelle: Enthalten in: npj vaccines
• Ort Quelle: [London] : Nature Publishing Group, 2016
• Jahr Quelle: 2023
• Band/Heft Quelle: 8(2023), Artikel-ID 112, Seite 1-17
• ISSN Quelle: 2059-0105
• DOI: doi:10.1038/s41541-023-00701-2
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Malaria
• Sach-SW: Protein vaccines
• K10plus-PPN: 1860340938

Abstract

Radical control of malaria likely requires a vaccine that targets both the asymptomatic liver stages and the disease-causing blood stages of the human malaria parasite Plasmodium falciparum. While substantial progress has been made towards liver stage vaccines, the development of a blood stage vaccine is lagging behind. We have recently conducted a first-in-human clinical trial to evaluate the safety and immunogenicity of the recombinant, full-length merozoite surface protein 1 (MSP1FL) formulated with GLA-SE as adjuvant. Here, we show that the vaccine, termed SumayaVac-1, elicited both a humoral and cellular immune response as well as a recall T cell memory. The induced IgG and IgM antibodies were able to stimulate various Fc-mediated effector mechanisms associated with protection against malaria, including phagocytosis, release of reactive oxygen species, production of IFN-γ as well as complement activation and fixation. The multifunctional activity of the humoral immune response remained for at least 6 months after vaccination and was comparable to that of naturally acquired anti-MSP1 antibodies from semi-immune adults from Kenya. We further present evidence of SumayaVac-1 eliciting a recallable cellular cytotoxicity by IFN-γ producing CD8+ T cells. Our study revitalizes MSP1FL as a relevant blood stage vaccine candidate and warrants further evaluation of SumayaVac-1 in a phase II efficacy trial.